Trinity Biotech plc

Trinity Biotech plc acquires together with its subsidiaries develops manufactures and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the Americas Africa Asia and Europe. The company offers clinical laboratory products including diagnostic tests and instrumentation which detect infectious diseases such as lyme disease; sexually transmitted diseases consisting syphilis and herpes; SARS-CoV-2; and epstein barr measles mumps toxoplasmosis cytomegalovirus rubella varicella and other viral pathogens as well as products for the in-vitro diagnostic testing for haemoglobin A1c used in the monitoring and diagnosis of diabetes and identifying those who are at a risk of developing diabetes. It also provides laboratory-testing services for Sjogren's syndrome hearing loss celiac disease lupus rheumatoid arthritis systemic sclerosis and other laboratory-testing services for autoimmune disorders. The company develops manufactures and sells products in the immunofluorescence assay enzyme-linked immunosorbent western blot and line immunoassay formats; and provides reagent products such as ACE bile acids lactate oxalate and glucose-6-phosphate dehydrogenase for diagnosis of liver and kidney diseases as well as haemolytic anaemia. In addition the company sells raw materials to the life sciences industry and research institutes. It serves public health authorities non-governmental organisations and clinical and reference laboratories through its direct sales force as well as through a network of independent distributors and strategic partners. Trinity Biotech plc was incorporated in 1992 and is headquartered in Bray Ireland.